Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: INCMGA-0012; INCMGA00012; MGA 012

Latest Information Update: 29 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Developer Incyte Corporation; MacroGenics; ZAI Lab
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Gastric cancer; Oesophageal cancer
  • Phase II Anal cancer; Endometrial cancer; Merkel cell carcinoma; Solid tumours
  • Phase I/II Colorectal cancer
  • Phase I Acute myeloid leukaemia
  • No development reported Haematological malignancies

Most Recent Events

  • 18 Jan 2020 Incyte Corporation plans the phase II trial for Penile Cancer (Late-stage disease, First-line therapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in March 2020 in Germany, Italy and Spain (NCT04231981) (IV, Infusion)
  • 13 Jan 2020 University of Pennsylvania and Incyte Corporation plan a phase II trial for Glioblastoma (Combination therapy, Recurrent, Neoadjuvant therapy) in USA in January 2020 (NCT04225039)
  • 19 Dec 2019 Incyte Corporation plans the phase III POD1UM-304 trial for Squamous and Non-squamous non-small cell lung cancer (Metastatic disease, Combination therapy, First-line therapy) in February 2020 (NCT04205812)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top